Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel Free ZVSA Stock Alerts

ZyVersa Therapeutics (ZVSA) Competitors

ZyVersa Therapeutics logo
$0.0001 0.00 (0.00%)
As of 11/12/2026 02:04 PM Eastern
Compare

ZVSA vs. LIPO, ALVOW, APLMW, ARAV, and BIAFW

Should you buy ZyVersa Therapeutics stock or one of its competitors? ZyVersa Therapeutics's main competitors and comparable companies include Lipella Pharmaceuticals (LIPO), Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), and bioAffinity Technologies (BIAFW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ZyVersa Therapeutics compare to Lipella Pharmaceuticals?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

ZyVersa Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

ZyVersa Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. ZyVersa Therapeutics' return on equity of -109.54% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ZyVersa TherapeuticsN/A -109.54% -43.95%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
ZyVersa Therapeutics Neutral
Lipella Pharmaceuticals Neutral

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lipella Pharmaceuticals has higher revenue and earnings than ZyVersa Therapeutics. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A
Lipella Pharmaceuticals$536.36K0.01-$5.02M-$2.42N/A

Summary

ZyVersa Therapeutics and Lipella Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Alvotech?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Alvotech has higher revenue and earnings than ZyVersa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A
Alvotech$491.95MN/AN/AN/AN/A

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alvotech had 8 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 8 mentions for Alvotech and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 beat Alvotech's score of -0.02 indicating that ZyVersa Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
ZyVersa Therapeutics Neutral
Alvotech Neutral

Alvotech's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ZyVersa TherapeuticsN/A -109.54% -43.95%
Alvotech N/A N/A N/A

Summary

Alvotech beats ZyVersa Therapeutics on 4 of the 7 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

In the previous week, Apollomics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for ZyVersa Therapeutics. Apollomics' average media sentiment score of 1.79 beat ZyVersa Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
ZyVersa Therapeutics Neutral

Apollomics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
ZyVersa Therapeutics N/A -109.54%-43.95%

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ApollomicsN/AN/AN/AN/AN/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

Summary

Apollomics beats ZyVersa Therapeutics on 4 of the 6 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Aravive's average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company Overall Sentiment
Aravive Neutral
ZyVersa Therapeutics Neutral

Aravive is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

35.8% of Aravive shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aravive's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
ZyVersa Therapeutics N/A -109.54%-43.95%

Summary

Aravive beats ZyVersa Therapeutics on 4 of the 6 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, bioAffinity Technologies had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for ZyVersa Therapeutics. bioAffinity Technologies' average media sentiment score of 1.25 beat ZyVersa Therapeutics' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Positive
ZyVersa Therapeutics Neutral

bioAffinity Technologies' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
ZyVersa Therapeutics N/A -109.54%-43.95%

bioAffinity Technologies has higher revenue and earnings than ZyVersa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

bioAffinity Technologies beats ZyVersa Therapeutics on 5 of the 7 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVSA vs. The Competition

Export
MetricZyVersa TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$4.08B$7.85B$12.00B
Dividend YieldN/A3.62%2.46%4.50%
P/E Ratio0.0024.5134.4330.31
Price / SalesN/A16.788.845.84
Price / CashN/A26.8922.2322.80
Price / Book0.004.114.383.77
Net Income-$9.41M-$22.78M$3.51B$390.69M
7 Day PerformanceN/A-3.18%-1.80%-0.60%
1 Month PerformanceN/A-6.16%-4.19%-6.88%
1 Year PerformanceN/A-0.85%0.57%-6.20%

ZyVersa Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVSA
ZyVersa Therapeutics
N/A$0.00
flat		N/A-99.9%$1KN/AN/A2
LIPO
Lipella Pharmaceuticals
N/A$0.00
flat		N/A-99.9%$2K$536.36KN/A7
ALVOW
Alvotech
N/A$0.14
flat		N/A-84.7%$0.00$491.95MN/A1,460
APLMW
Apollomics
N/A$0.01
flat		N/A-47.2%$0.00$8.50MN/A15
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...
USA Capital Gold | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel